Thermo Fisher ScientificFinancial data tables
Thermo Fisher Scientific (TMO) figures from its financial statements (company filings via Financial Modeling Prep), in US dollars; non-US reporters are converted to US dollars. Periods carry the company's own fiscal quarter and year, as its filings name them, with the date each period ended. Source filings are on the Filings tab.
| Period | Revenue | Gross profit | Operating income | Net income | Diluted EPS | Gross margin | Operating margin |
|---|---|---|---|---|---|---|---|
| Q3 FY2026 (ended Sep 26, 2026) | $12.14B | $5.19B | $2.26B | $1.72B | $4.64 | 42.8% | 18.6% |
| Q2 FY2026 (ended Jun 27, 2026) | $11.99B | $4.94B | $2.09B | $1.74B | $4.68 | 41.2% | 17.4% |
| Q1 FY2026 (ended Mar 28, 2026) | $11.01B | $4.48B | $1.86B | $1.65B | $4.43 | 40.7% | 16.9% |
| Q4 FY2025 (ended Dec 31, 2025) | $12.21B | $5.01B | $2.30B | $1.98B | $5.21 | 41.0% | 18.9% |
| Q3 FY2025 (ended Sep 27, 2025) | $11.12B | $4.58B | $2.08B | $1.62B | $4.27 | 41.2% | 18.7% |
| Q2 FY2025 (ended Jun 28, 2025) | $10.85B | $4.41B | $1.92B | $1.62B | $4.28 | 40.6% | 17.7% |
| Q1 FY2025 (ended Mar 29, 2025) | $10.36B | $4.25B | $1.84B | $1.51B | $3.98 | 41.0% | 17.8% |
| Q4 FY2024 (ended Dec 31, 2024) | $11.39B | $4.47B | $2.27B | $1.83B | $4.78 | 39.2% | 19.9% |
| Period | Operating cash flow | Capital expenditures | Free cash flow | Share repurchases | Dividends paid |
|---|---|---|---|---|---|
| Q3 FY2026 (ended Sep 26, 2026) | $2.55B | $437.0M | $2.11B | $0.0M | $174.0M |
| Q2 FY2026 (ended Jun 27, 2026) | $2.13B | $450.0M | $1.68B | $1.00B | $175.0M |
| Q1 FY2026 (ended Mar 28, 2026) | $1.19B | $376.0M | $816.0M | $3.00B | $162.0M |
| Q4 FY2025 (ended Dec 31, 2025) | $3.46B | $465.0M | $2.99B | $3.00B | $162.0M |
| Q3 FY2025 (ended Sep 27, 2025) | $2.24B | $404.0M | $1.83B | $2.00B | $163.0M |
| Q2 FY2025 (ended Jun 28, 2025) | $1.40B | $294.0M | $1.10B | $0.0M | $162.0M |
| Q1 FY2025 (ended Mar 29, 2025) | $723.0M | $362.0M | $361.0M | $2.00B | $149.0M |
| Q4 FY2024 (ended Dec 31, 2024) | $3.29B | $480.0M | $2.81B | $1.00B | $149.0M |
| Period | Total assets | Cash and equivalents | Short-term investments | Total debt | Total equity |
|---|---|---|---|---|---|
| Q3 FY2026 (ended Sep 26, 2026) | $114.23B | $5.46B | $600.0M | $41.37B | $54.76B |
| Q2 FY2026 (ended Jun 27, 2026) | $113.17B | $4.06B | $0.0M | $42.55B | $52.68B |
| Q1 FY2026 (ended Mar 28, 2026) | $113.28B | $3.25B | $2.0M | $43.16B | $51.93B |
| Q4 FY2025 (ended Dec 31, 2025) | $110.34B | $9.85B | $253.0M | $39.38B | $53.41B |
| Segment | Q2 FY2026 (ended Jun 27, 2026) | Q1 FY2026 (ended Mar 28, 2026) | Q4 FY2025 (ended Dec 31, 2025) | Q3 FY2025 (ended Sep 27, 2025) |
|---|---|---|---|---|
| Product revenues | $6.82B | |||
| Services | $5.17B | |||
| Service | $4.73B | $4.97B | $4.63B | |
| Consumables | $4.72B | $5.03B | $4.68B | |
| Instruments | $1.55B | $2.22B | $1.81B |
| Region | Q2 FY2026 (ended Jun 27, 2026) | Q1 FY2026 (ended Mar 28, 2026) | Q4 FY2025 (ended Dec 31, 2025) | Q3 FY2025 (ended Sep 27, 2025) |
|---|---|---|---|---|
| United States | $6.15B | $5.71B | $6.11B | $5.69B |
| Europe | $3.31B | $2.96B | $3.37B | $3.00B |
| Asia Pacific | $2.10B | $1.97B | $2.28B | $2.01B |
| All Other Countries | $430.0M | $372.0M | $462.0M | $415.0M |
| Year | Employees |
|---|---|
| 2025 | 125,000 |
| 2024 | 125,000 |
| 2023 | 122,000 |
| 2022 | 130,000 |
| 2021 | 130,000 |
| 2020 | 80,000 |
Thermo Fisher Scientific (TMO) reported revenue of $12.14B in Q3 2026, with Product revenues its largest revenue segment at 57%.